A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial,infratentorial, and spinal cord ependymoma |
| |
| Authors: | Mark R Gilbert Ying Yuan Jimin Wu Tito Mendoza Elizabeth Vera Antonio Omuro Frank Lieberman H Ian Robins Elizabeth R Gerstner Jing Wu Patrick Y Wen Tom Mikkelsen Kenneth Aldape Terri S Armstrong |
| |
| Affiliation: | 1. Center for Cancer Research, National Cancer Institute, Bethesda, Maryland;2. The University of Texas MD Anderson Cancer Center, Houston, Texas;3. Yale University, New Haven, Connecticut;4. University of Pittsburgh, Pittsburgh, Pennsylvania;5. University of Wisconsin–Madison, Madison, Wisconsin;6. Massachusetts General Hospital, Boston, Massachusetts;7. Dana Farber Cancer Institute, Boston, Massachusetts;8. Henry Ford Hospital, Detroit, Michigan |
| |
| Abstract: | BackgroundNo standard medical treatment exists for adult patients with recurrent ependymoma, and prospective clinical trials in this population have not succeeded because of its rarity and challenges in accruing patients. The Collaborative Ependymoma Research Network conducted a prospective phase II clinical trial of dose-dense temozolomide (TMZ) and lapatinib, targeting the unmethylated O6-methylguanine-DNA methyltransferase (MGMT) promoter status and increased expression of ErbB2 (human epidermal growth factor receptor 2) and ErbB1 (epidermal growth factor receptor) in ependymomas.MethodsPatients age 18 or older with histologically proven and progressive ependymoma or anaplastic ependymoma were eligible and received dose-dense TMZ and daily lapatinib. The primary outcome measure was median progression-free survival (PFS). Landmark 6- and 12-month PFS and objective response were measured. Serial assessments of symptom burden using the MD Anderson Symptom Inventory Brain Tumor (MDASI-BT)/MDASI–Spine Tumor modules were collected.ResultsThe 50 patients enrolled had a median age of 43.5 years, median Karnofsky performance status of 90, and a median of 2 prior relapses. Twenty patients had grade III, 16 grade II, and 8 grade I ependymoma. Half had spinal cord tumors; 15 had a supratentorial tumor, 8 infratentorial, and 2 had disseminated disease. Treatment was well tolerated. The median PFS was 7.8 months (95% CI: 5.5,12.2); the 6- and 12-month PFS rates were 55% and 38%, with 2 complete and 6 partial responses. Measures of symptom burden showed reduction in moderate-severe pain and other disease-related symptoms in most patients.ConclusionsThis treatment, with demonstrated clinical activity with objective responses and prolonged disease control associated with disease-related symptom improvements, is an option as a salvage regimen for adult patients with recurrent ependymoma. |
| |
| Keywords: | combination chemotherapy ependymoma lapatinib progression-free survival temozolomide |
|
|
